Image of red rose

Treatment Monitoring & Surveillance Phase

Advanced imaging technologies, such as GE’s molecular breast imaging, PET/CT and PET/MR, can help clinicians to carefully monitor patients’ treatment with precise visualization and tracking of metabolic activity and disease progression. Armed with data, such as reliable quantitative SUV values, clinicians can obtain important insights on treatment effectiveness to help optimize care.

Treatment Monitoring & Surveillance Phase

Breast Health Advantage

GE Breast Health Advantage

It’s not easy. The competition for patients and physicians is fierce. The reimbursement landscape is shifting. Technology continues to evolve and improve, but where it best fits in the care pathway is not always clear. The Patient Protection and Accountable Care Act is providing coverage to an estimated incremental 746,000 women for important screenings by 20191, yet the U.S. Preventative Services Task Force (USPSTF) recommends reductions in the frequency of screening. And, nearly half of all women could have elevated risks or complicating factors2,3 that may require a screening and diagnostic personalized approach.

In addition to managing these market challenges, you may want to focus on lowering recall rates, shortening times from screening to diagnosis, and gaining important insights that will help inform treatment decisions for each woman. In today’s cost-constrained environment, it’s important to ensure your investments in strengthening and expanding your capabilities pay off for your facility, and work hard for your patients. That’s why it’s critical to have a trusted, committed team to help you deliver the care your patients need — and to help you meet your financial and operational objectives.

That’s why we offer the GE Breast Health Advantage.

 

 

1 Banjo, Solomon. The Advisory Board Company. Imaging Performance Partnership. (2014). Breast Imaging Update: Current Market Outlook and Update on Digital Breast Tomosynthesis.

2 Tabár L, et al. (2011). Swedish Two County Trial: Impact of Mammographic. 260: 658 63.

3 American Cancer Society. (2015) Cancer Facts & Figures 2015.